Journal
NEUROLOGY
Volume 81, Issue 24, Pages 2103-2106Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/01.wnl.0000437306.37850.22
Keywords
-
Categories
Funding
- Marie Curie Intra-European Fellowship
- Marie Curie International Incoming Fellowship
- Fund for Scientific Research, Flanders, Belgium (FWO)
- European Research Council
- Queen Elisabeth Foundation
- Fonds voor wetenschappelijk onderzoek FWO)
- KU Leuven
- VIB
- Flemish Government
- Arthur Bax
- Anna Van Luffelen fund
Ask authors/readers for more resources
Objective: We evaluated microRNAs (miRNAs) as potential biomarkers for Alzheimer disease (AD) by analyzing the expression level of miRNAs in CSF of patients with AD dementia and nonaffected control subjects. Methods: Using quantitative PCR, we profiled the expression level of 728 miRNAs in CSF of nonaffected control subjects and patients with clinically ascertained AD dementia, and we further compared the expression level of candidate miRNAs in 37 control subjects and 35 patients with AD dementia. Results: The level of hsa-miR-27a-3p in CSF is reduced in patients with dementia due to AD in 2 different cohorts of subjects (cohort 1: p = 0.008; cohort 2: p = 0.015; 2-tailed unpaired Welch t test). Moreover, low levels of hsa-miR-27a-3p were accompanied by high CSF tau levels and low CSF beta-amyloid levels. Conclusions: Our pilot study highlights hsa-miR-27a-3p as a candidate biomarker for AD and provides the groundwork for further confirmation studies in larger cohorts and in other hospitals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available